Amneal Pharmaceuticals: Shares Still Feel Significantly Undervalued
Amneal Pharmaceuticals, Inc. offers strong growth prospects with undervalued stock, rising revenues, reduced debt, and key ...
Paul Skenes in Year 2: Rethinking what's possible
An eager crowd awaits, perhaps 300 strong. Some jockey for position under the temporary tent erected in the gravel parking ...
Quiver Bioscience Announces Collaboration with the Dup15q Alliance to Advance Antisense Oligonucleotide Therapeutic Program
Quiver Bioscience announces collaboration with Dup15q Alliance to advance an ASO therapeutic program for chromosome 15q duplication (Dup15q) syndrome.
Alumis Reports Year End 2024 Financial Results and Highlights Recent Achievements
Presented Phase 2 STRIDE OLE 52-week psoriasis data at AAD 2025 demonstrating next-generation oral TYK2 inhibitor ESK-001 treatment led to robust long-term clinical responses and was well tolerated; ...
Applied Therapeutics Appoints Todd F. Baumgartner, MD, MPH as Chief Regulatory Officer
Applied Therapeutics, Inc. (Nasdaq: APLT), a biopharmaceutical company dedicated to creating transformative treatments for rare disease, today announced the ...
Black Diamond Therapeutics, Inc: Servier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933, A Targeted Oncology Therapy
The partnership underscores Servier's commitment to developing targeted therapies that address unmet medical needs in oncologyServier will develop and commercialize BDTX-4933, a Phase 1 asset with bes ...
PharmiWeb20h
New data on investigational therapy for thymidine…
UCB, a global biopharmaceutical company, today announced positive data from studies involving its investigational pyrimidine nucleoside therapy, doxecitine (dC) and doxribtimine (dT), in people living ...